🕒 Last update: loading…

Stock Sorrento Therapeutics, Inc. SRNE

Sorrento Therapeutics, Inc. — Investlytic score 0/5 on the five criteria.

-
-
0/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 0/5 criteria met.

  • ❌ Price trend failed
  • ⚠️ Mixed growth
  • ❌ Debt failed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2018 → 2019: 40.83%

Price change 2019 → 2020: 101.92%

Price change 2020 → 2021: -31.87%

Price change 2021 → 2022: -80.95%

Price change 2022 → 2023: -65.32%

Price change 2023 → 2024: -83.73%

Price change 2024 → 2025: 420.00%

Price change 2025 → 2026: -69.23%

Price change 2026 (year to date): -74.60%

Financial growth

Revenue CAGR (8 years): 45.33%

Earnings CAGR (8 years): N/A

Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.

Debt

Debt-to-equity ratio: 134504000.00

Debt/equity > 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: -0.02

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 75.76% from the high over 6 months.

Excessive correction (> 20.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…
03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by Sorrento Therapeutics, Inc. over the latest fiscal years.

Revenue
62.8 m USD
fiscal year 2022
Net income
-573 m USD
fiscal year 2022
Net margin
-911.6 %
fiscal year 2022
Average annual growth
-16.2 %
Revenue growth over 5 years
Average annual growth
+59.7 %
Revenue growth over 10 years
Market cap
165,384 USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
2017152 m9.1 m6.0 %n/a
201821.2 m-204 m-960.4 %-86.0 %
201931.4 m-359 m-1,142.5 %+48.3 %
202040.0 m-298 m-746.4 %+27.2 %
202152.9 m-429 m-810.9 %+32.3 %
202262.8 m-573 m-911.6 %+18.8 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by Sorrento Therapeutics, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
fragile accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
-10.88
risk zone (below 1.81)
Piotroski Score
3 / 9
0 to 3: fragile accounts
Net Debt / EBITDA
-0.21 x
net cash
Fiscal year202020212022
Cash and investments56.5 m127 m50.0 m
Total Debt169 m238 m135 m
Net Debt113 m201 m111 m
Equity165 m78.7 m-18.6 m
Total assets536 m695 m473 m
Operating cash flow-160 m-282 m-294 m
Investments (capex)37.6 m8.9 m13.7 m
Free cash-flow-197 m-291 m-308 m
Share buybacks55.0 m00
Dividends paid000

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / book value-0.01 x
Return on Equity (ROE)-1,904.9 %
Return on Invested Capital (ROIC)-286.8 %
Net margin-911.6 %
Debt / equity-7.23 x
Current ratio0.29 x
Interest coverage-58.82 x

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 20/11/2026.

+

Valuation and competitors

Sorrento Therapeutics, Inc. compared with its sector on the same exchange and with its main competitors.

Direct competitors

CompanyMarket cap (USD)P/ENet margin
Sorrento Therapeutics, Inc.165,384n/an/a
Ensysce Biosciences, Inc. ENSC8.1 mn/a-200.8 %
Doseology Sciences Inc. DOSEF433,355n/a-1,052.2 %
Futura Medical plc FAMDF1.1 mn/a-534.6 %
Core One Labs Inc. CLABF471n/an/a
ProText Mobility, Inc. TXTM73.0 mn/a0.0 %
Evolutionary Genomics, Inc. FNAM1,331n/an/a
Kane Biotech Inc. KNBIF4.8 mn/a-636.0 %
MYND Life Sciences Inc. MYNDF657,843n/an/a

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.

+

Dividends and earnings

Sorrento Therapeutics, Inc.: dividend history, last distributions, stock splits and earnings releases.

No known dividend for this company.

Stock splits

DateOperation
01/08/2013reverse split: 1 share for 25
07/10/2008reverse split: 1 share for 10
16/03/2007reverse split: 1 share for 20

Factual data: ex-dividend history and earnings calendar, as of 20/11/2026. A past dividend does not guarantee the next one.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in Sorrento Therapeutics, Inc.

Free float
97.8 %
share of freely traded shares

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 14/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
OTC (hors cote)
IPO: 19/01/2007
ISIN code
US83587F2020
Workforce
949
full-time employees
Chief executive
Henry H. Ji

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Sorrento Therapeutics, Inc.

What is the Sorrento Therapeutics, Inc. share price?

Latest recorded price: 0.0003 USD on 13/11/2026, for a market cap of 165,384 USD.

What is the revenue of Sorrento Therapeutics, Inc.?

62.8 m USD for fiscal year 2022, with net income of -573 m USD (net margin -911.6 %).

Is Sorrento Therapeutics, Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US83587F2020).

How many employees does Sorrento Therapeutics, Inc. have?

949 full-time employees according to the latest published profile.

Who runs Sorrento Therapeutics, Inc.?

Henry H. Ji is the company's chief executive.